CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM...
Phase 1
San Francisco, California, United States and 4 other locations
efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma...
Phase 1, Phase 2
San Francisco, California, United States and 20 other locations
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)...
Phase 1, Phase 2
Palo Alto, California, United States and 6 other locations
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/II....
Phase 2, Phase 3
San Francisco, California, United States and 61 other locations
chemo-radiotherapy and plerixafor in treating patients with glioblastoma (brain tumor). Radiation therapy uses high energy x-rays to kill tu...
Phase 2
Palo Alto, California, United States
Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the stud...
Phase 3
Palo Alto, California, United States and 27 other locations
with ipilimumab and surgery when used in the treatment of recurrent glioblastoma.The names of the study drugs involved in this study are:* N...
Phase 1
Stanford, California, United States and 3 other locations
of this study is to determine the safety and efficacy of the combination therapy of TTFields + SRS+ Temozolomide (TMZ) for newly diagnosed glioblastoma...
Phase 1
Stanford, California, United States
This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM).The following intervent...
Phase 2
San Francisco, California, United States and 6 other locations
The purpose of this first-in-human (FIH) study of \[177Lu\]-NeoB is to characterize the safety, tolerability, pharmacokinetics (PK) as well as the di...
Phase 1, Phase 2
Stanford, California, United States and 10 other locations
Clinical trials
Research sites
Resources
Legal